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Regression of Established AB1 Murine Mesothelioma
Induced by Peritumoral Injections of CpG
Oligodeoxynucleotide Either Alone or in Combination with
Poly(I:C) and CD40 Ligand Plasmid DNA
Geoffrey W. Stone, PhD,* Suzanne Barzee, BS,* Victoria Snarsky, MSc,* Camila Santucci, RVT,*
Brian Tran, BS,* and Richard S. Kornbluth, MD, PhD*†
Introduction: Stimulation of the CD40 receptor using an agonistic
anti-CD40 antibody can slow the growth of AB1 tumors. Stimula-
tion of the GITR receptor may also have antitumor activity by
countering the immunosuppressive effects of regulatory CD4 T
cells. Similarly, agonists for Toll-Like Receptors (TLR) such as
CpG oligodeoxynucleotides (TLR9 agonist) have activity against
AB1 tumors. Combinations of CpG with CD40 ligand and polyi-
nosinic-polycytidylic acid (poly(I:C), TLR3 agonist) may be even
stronger than CpG alone. The synergistic effects of these combina-
tions have been tested in other tumor types but not in mesothelioma.
Methods: Established AB1 mesothelioma tumors were injected
with either plasmid DNA encoding a novel 4-trimer form of murine
CD40 ligand (pSP-D-CD40L), GITR ligand (GITRL), or control
plasmid DNA. In addition, CpG with or without poly(I:C) was also
injected intratumorally.
Results: Plasmid injections of pSP-D-CD40L or pSP-D-GITRL,
had no significant antitumor effect, possibly reflecting the difficulty
of administering DNA injections into this very dense tissue. How-
ever, the injection of CpG with or without poly(I:C) strongly
suppressed tumor growth and led to long-term tumor-free survival.
The response to a triple combination of pSP-D-CD40L  CpG 
poly(I:C) was demonstrated by an increase in intratumoral CD8 T
cells and a dramatic increase in F4/80 macrophages.
Conclusions: Intratumoral injections of plasmid DNAs encoding
highly active forms of either CD40 ligand or GITR ligand had no
significant antitumor effects in this model, although improved DNA
delivery techniques could possibly improve this strategy. In contrast,
intratumoral CpG injections had significant antitumor effects and
there were indications that CpG plus poly(I:C) was even more
effective. Taken together, these data confirm previous reports that
immune stimulants, especially CpG TLR9 agonists, have potential
as a treatment for mesothelioma.
Key Words: Tumor immunity, Vaccination, Dendritic cells, Monocyte/
macrophages, Mesothelioma, CD40, GITR, TLR3, TLR9.
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The local application of Toll-Like Receptor (TLR) agonistsmay have antitumor effects.1,2 Equally promising in mice
but difficult to apply in humans, is the use of CD40 stimu-
lation. Numerous studies have shown that agonistic antibody
to CD40 can have major antitumor effects either on its own3,4
or when combined with TLR agonists.5,6 However, agonistic
anti-CD40 antibody can be toxic, especially if used repeat-
edly.3,7 The van Mierlo group noted death of 50% of mice
following a second intravenous injection of anti-CD40 anti-
body. Intratumoral injections of an adenovirus expressing
CD40L has also been shown to be effective against mesothe-
lioma in mice.8
From an immunologic point of view, most of these
immunostimulants activate dendritic cells (DCs), shifting
them from their resting, tolerogenic state to that of fully
effective antigen presenting cells. These immunostimulants
counteract the deactivating effects of tumors on the DCs in
their environment.9 For IL-12p70 production, for example,
Napolitani et al.10 found that the combination of two TLR
agonists (e.g., poly(I:C) for TLR3 and R-848 for TLR7/8)
was markedly synergistic, and 10-fold more IL-12p70 was
produced when CD40L was added to the cultures. In vivo,
these findings have correlates in reports that CD40 stimula-
tion combined with TLR agonists is capable of inducing
strong antitumor CD8 T cell activity.5,6
This study examined the effects on established AB1
mesothelioma of combinations of TLR agonists along with a
new form of CD40L (4-trimer SP-D-CD40L) that dramati-
cally enhanced CD8 T cell responses in a murine DNA
vaccine model.11 In addition, a 4-trimer form of GITR ligand
(pSP-D-GITRL) was tested, based on the concept that stim-
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ulation of the GITR receptor can antagonize the immunosup-
pressive effects of regulatory CD4 T cells found in many
tumors.12 CpG and poly(I:C) showed activity against AB1
tumors when injected directly into established tumors every
other day  5. In addition, synergies between these two TLR
agonists and between pSP-D-CD40L and TLR agonists were
indicated in some experiments, suggesting that these combi-
nations should be studied further.
MATERIALS AND METHODS
Plasmids
CD40L and GITRL plasmids were previously de-
scribed.11,13 Plasmids tested include: pSP-D-CD40L; pSP-D-
GITRL; pIFN (pORF5-mIFNG, InVivoGen, San Diego,
CA); and pcDNA3.1() (Invitrogen, Carlsbad, CA) as vector
control.
Plasmid Preparation
Plasmids were isolated by anion-exchange chromatog-
raphy resin (EndoFree Plasmid MaxiKit, QIAgen, Inc, Va-
lencia, CA). An additional purification step using Triton
X-114 detergent extraction was used to further purify plas-
mid.14 Before injection, plasmid DNA was diluted in Dul-
becco calcium- and magnesium-free phosphate buffered sa-
line (PBS) to 1 mg/ml (50 g per 50 l injection).
TLR Agonists
TLR agonist compounds were prepared following their
manufacturer’s instructions. TLR3 agonist poly(I:C) (Amer-
sham, Piscataway, NJ) was administered at 25 g per injection
in PBS. TLR9 agonist CpG 1018 5-TGACTGTGAACGTTC-
GAGATGA-3 (all DNA linkages phosphorthioate) was a gift
of Dr. Eyal Raz15 or was purchased from Trilink Biotechnolo-
gies (San Diego, CA). CpG was administered at 25 g per
injection in PBS. All solutions were endotoxin free.
Tumor Cell Lines
The AB1 malignant mesothelioma tumor cell line was
derived by asbestos treatment of BALB/c mice by Dr. Bruce
Robinson,16 and was obtained through Dr. Steven Albelda,
University of Pennsylvania. The A20 tumor cell line was
obtained from the ATCC. All cell lines were cultured in
RPMI 1640, 2 mM L-glutamine, and 10% FBS.
Tumor Challenge and Immunotherapy
Mice studies were approved by the Institutional Animal
Care and Use Committee of the VA San Diego Healthcare
System. Tumor cells were detached using trypsin/EDTA
followed by neutralization with cold RPMI  10% FBS and
pelleting at 300  g for 6 minutes. Cells were washed three
times with cold PBS and resuspended at 5  106 cells/ml in
PBS. To initiate tumors, a total of 5 105 cells (0.1 ml) were
injected subcutaneously into the abdomen of 6 to 8 week old
female BALB/cByJ mice (Jackson Labs, Bar Harbor, ME).
Five mice/group were used for each condition. When tumors
became palpable, they were measured on two orthogonal axes
using an electronic caliper and the diameter was recorded as
the mean of the two measurements. Once the tumors measured
4 mm in mean diameter, a total of 50 l of test substance was
injected into or around the tumor using a 0.5 ml insulin syringe.
The peritumoral injections were repeated every other day for a
total of five injections. Mice were euthanized when tumors
became 15 mm in mean diameter or ulcerated.
Tumor Rechallenge
Sixty days after initial AB1 injection, tumor-free sur-
vivors were rechallenged s.c. either with 1  105 AB1 cells
or 1  105 A20 lymphoma cells. Tumor growth was mea-
sured from day 12 and every other day until all mice that
became tumor-bearing were euthanized.
Tumor Histology
Mice with established tumors (as detailed above) at 7
mm diameter were given peritumoral injections of immuno-
stimulatory compounds every other day  5 and euthanized
2 days after the final dose. The tumors were then excised and
divided. Half was fixed in 1% paraformaldehyde and embed-
ded in paraffin, and the other half was flash frozen in OCT
compound. Serial sections (10 m in thickness) were ob-
tained. For immunostaining the following primary antibodies
were used: CD11c clone HL3 (BD Pharmingen, San Diego,
CA); CD8 clone 53–6.7 (BD Pharmingen); and F4/80 clone
BM8 (eBioscience, San Diego, CA). Slides were examined
with a Zeiss Axioskop microscope and images were recorded
using an Optronics CCD camera. Duplicate tumors were
evaluated for each condition.
Statistics
Geometric mean tumor sizes were compared using Stu-
dent t test (Prism 4.0 Software, GraphPad Systems, San Diego,
CA). A log-rank test was used to determine the significance of
the differences between groups in Kaplan-Meier survival plots.
A p value of 0.05 was considered significant.
RESULTS
Construction of 4-Trimer Soluble CD40L Fused
with the Body of Surfactant Protein D
In a previous vaccine study we found that plasmids
encoding soluble forms of CD40L had adjuvant activity when
combined with plasmids for HIV antigens. The most active form
of CD40L in those studies was a 4-trimer form produced as a
fusion protein with the body of pulmonary surfactant protein D
(SP-D)11,17 (Figure 1).
FIGURE 1. Depiction of SP-D-CD40L. Using recombinant
DNA techniques, the N-terminal portion of murine pulmo-
nary surfactant protein D (minus the carbohydrate recogni-
tion domain) was fused to the entire extracellular domain of
murine CD40L. The resulting molecule is expected to form a
4-trimer cruciate homododecamer as shown.
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For Established AB1 Mesothelioma, pSP-D-
CD40L, and pSP-D-GITRL Alone were Inactive
but a Triple Combination of pSP-D-CD40L 
CpG  poly(I:C) Cured a Majority of Treated
Mice
To determine if pSP-D-CD40L or pSP-D-GITRL had
antitumor effects for mesothelioma, AB1 tumor cells were
injected subcutaneously into BALB/c mice and treated
FIGURE 2. Combinations of pSP-D-CD40L, CpG, and
poly(I:C) showed strong antitumor effects against estab-
lished AB1 mesothelioma. AB1 cells were injected s.c. in
BALB/c mice. When the tumors were 4 mm in diameter,
they were injected every other day  5 with 50 g of plas-
mid DNA or 25 g of TLR agonists or their combinations.
Panel A, For AB1 mesothelioma, neither pSP-D-CD40L nor
pSP-D-GITRL had an effect on tumor growth. However, the
combination of pSP-D-CD40L  CpG or the triple combina-
tion of pSP-D-CD40L  CpG  poly(I:C) significantly re-
duced tumor growth compared with phosphate buffered
saline or pcDNA3.1 (p  0.05 for pSP-D-CD40L  CpG and
p  0.01 for pSP-D-CD40L  CpG  Poly(I:C) from day 20
by Student t test). In those cases, many of the established
tumors regressed entirely following treatment, an effect
never seen under other conditions. Panel B, Combinations
that included CpG significantly enhanced survival and cured
mice of established AB1 mesothelioma. Consistent with the
tumor growth data, there was no survival benefit using pSP-
D-CD40L or pSP-D-GITRL alone. However, the two combina-
tions that included CpG had significant effects on survival. Re-
markably, the triple combination of pSP-D-CD40L  CpG 
poly(I:C) cured 5/6 mice which remained tumor free for more
than 4 months.
FIGURE 3. CpG alone or combinations that included CpG
showed strong antitumor effects on established AB1 mesotheli-
oma. As in Figure 2, AB1 tumors were established and treated
with injections of test substances every other day  5 begin-
ning when the tumors were 4 mm in diameter. For these
experiments, the plasmid DNA was extracted with Triton
X-114 to remove adventitious immunostimulatory compounds.
Panel A, CpG or combinations that included CpG significantly
slowed tumor growth. As before, pSP-D-CD40L did not slow
AB1 mesothelioma growth. However, both CpG and CpG 
poly(I:C) had significant antitumor effects compared with phos-
phate buffered saline from day 18 (p  0.05 by Student t test).
The double combination of TLR agonists CpG  poly(I:C)
slowed tumor growth, but this was not significantly greater
than using CpG alone in this experiment. For combinations
that included pSP-D-CD40L, this molecule made a significant
difference for two combinations when compared with
pcDNA3.1 as a control: pSP-D-CD40L  CpG (p  0.01 from
day 16); and pSP-D-CD40L  CpG  poly(I:C) (p  0.05 from
day 16). However, the substitution of control plasmid
pcDNA3.1 for pSP-D-CD40L in the triple combination with
CpG  poly(I:C) did not significantly reduce the antitumor ef-
fect. Because of the restricted time axis, this graph does not
indicate the complete regression of individual tumors produced
by CpG-containing treatments, as reflected in the tumor-free
survival data in Panel B. Panel B, CpG or combinations that in-
cluded CpG led to long term tumor-free survival. As before,
pSP-D-CD40L did not lead to long term tumor free survival.
For CpG alone, 60% of mice were long term tumor-free survi-
vors in this experiment. Similarly, the combination of CpG with
either pSP-D-CD40L or control pcDNA3.1 led to long term tu-
mor-free survivors, and this was statistically significant when
compared with pcDNA3.1 alone (p  0.01). This indicated that
CpG was the dominant factor in the antitumor effects observed.
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with various combinations. Although pSP-D-CD40L and
pSP-D-GITRL produced significant antitumor effects in
two other tumor systems, B16F10 melanoma and A20
lymphoma, respectively (data not shown), they had no
effect on the growth of established AB1 mesothelioma or
the survival of mice bearing this tumor (Figure 2). How-
ever, given the strong synergy reported for CD40 stimu-
lation combined with TLR stimulation,5,10 the combination
of pSP-D-CD40L with CpG oligodeoxynucleotide (ODN)
and the combination of CpG ODN and poly(I:C) were also
tested. As shown in an initial experiment, combinations of
pSP-D-CD40L with one or more TLR agonists led to
marked antitumor responses. Remarkably, the triple com-
bination of pSP-D-CD40L, CpG ODN, and poly(I:C) cured
a significant number of mice (Figure 2). It was also noted
that mice receiving treatments containing SP-D-CD40L
or GITRL displayed no signs of toxicity up to 1 year
after vaccination, consistent with previous DNA vaccine
studies.11
For Established AB1 Mesothelioma, CpG was
the Most Active Component of the Triple
Therapy Regimen
Given the promising results shown in Figure 2, a
number of additional controls were tested. As shown in
Figure 3, pSP-D-CD40L alone again had no significant anti-
tumor effect. The triple combination of a plasmid  CpG 
poly(I:C) again showed strong antitumor effects, which were
just as effective if the plasmid was control pcDNA3.1 rather
than pSP-D-CD40L. Importantly, however, CpG alone was
remarkably effective as an antitumor agent under these
conditions.
The Combination of Plasmids for CD40L and
IFN- was not Effective Against AB1
Mesothelioma
Although CD40L is an important stimulus for IL-12p70
production, it is not effective without a second stimulus such
as a TLR agonist18–20 or IFN-.18,21,22 Consequently, pSP-D-
CD40L was tested in combination with plasmid DNA for
IFN- and injected into established AB1 tumors as previously
described. As shown in Figure 4, the combination of pSP-D-
CD40L  pIFN- had no significant antitumor effects under
the same conditions where combinations containing CpG
were highly effective, as judged by either tumor growth
(Panel A) or survival (Panel B).
Mice Cured of AB1 Mesothelioma Tumors
were Resistant to Rechallenge with the Same
Tumor Type
Mice cured of AB1 mesotheliomas for 2 months were
rechallenged with the same or an unrelated tumor cell line. As
shown in Figure 5, these mice were protected from challenge
with the homologous AB1 tumor, but they remained suscep-
FIGURE 4. The combination of plasmids for CD40L and
IFN- had no effect on AB1 mesothelioma. Because IFN-
has been reported to synergize with CD40 stimulation, the
antitumor effects of pSP-D-CD40L  pIFN- were studied.
However, there were no antitumor effects from these plas-
mids either alone or in combination, as judged by tumor
growth measurements (Panel A) or survival (Panel B). As be-
fore, the triple combination of pSP-D-CD40L  CpG 
poly(I:C) led to tumor regressions and long term tumor-free
survival (p  0.01 compared with pcDNA3.1).
FIGURE 5. Mice cured of AB1 mesothelioma resist homol-
ogous tumor challenge. Mice that were cured of established
AB1 mesothelioma following treatment with the triple com-
bination of pSP-D-CD40L  CpG  poly(I:C) were rested for
2 months and then challenged with either AB1 mesotheli-
oma or A20 B cell lymphoma, an unrelated tumor of BALB/c
mice. As determined by tumor growth, the mice cured of
AB1 mesothelioma tumors completely suppressed the
growth of the homologous tumor cell line. This was specific,
however, as the unrelated A20 B cell lymphoma tumors
grew in an unrestrained manner in the AB1-cured mice. All
of the AB1-cured mice that were rechallenged with AB1 tu-
mors survived until the end of the experiment 40 days later,
whereas none of the mice in the other groups survived.
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tible to heterologous A20 tumor cells (an unrelated B cell
lymphoma). In a repeat study, mice cured of AB1 for
greater than 90 days were also protected from rechallenge
with the homologous tumor cell line (data not shown).
These data are consistent with immunologic memory as the
basis for protection.
Regressing Tumors were Marked by an
Infiltration of CD8 T Cells and F4/80
Macrophages
Given the possible role of adaptive immunity in tumor
eradication, tumor sections were analyzed for the presence or
absence of immune cells, including DCs, CD8 T cells, and
macrophages. Palpable AB1 tumors were treated with pSP-D-
CD40L  CpG  poly(I:C) every other day times five,
followed by tumor dissection 2 days later. As shown by
hematoxylin and eosin staining (Figure 6A), AB1 tumors
treated with pSP-D-CD40L  CpG  poly(I:C) were
much less hypercellular, as an indication of cell loss.
To identify immune cells within the tumors, tumor sec-
tions were stained for the presence of CD11c DCs, CD8 T
cells, and F4/80 macrophages (Figure 6B, C, and D, respec-
tively). Tumors treated with pSP-D-CD40L CpG poly(I:C)
showed an overall decrease in the density of intratumoral DCs
(Figure 6B). This may have resulted from the activation of
these cells followed by their migration to the tumor-
draining lymph nodes as previously reported.23 At the
same time point, there was an increase in intratumoral
CD8 T cells (Figure 6C), suggesting a role for CD8 T
cell-mediated activity in the antitumor effects observed.
Surprisingly, the number of F4/80 macrophages in-
creased to become the majority of cells within the regress-
ing tumor (Figure 6D).
DISCUSSION
Numerous studies have shown that strong CD40 stim-
ulation can lead to the eradication of established tumors.3,24,25
FIGURE 6. Tumor-dependent differences in the immunohistology of induced tumor regression. Tumors were injected every
other day  5 with phosphate buffered saline as a control or with pSP-D-CD40L  CpG  poly(I:C). As shown in Figures 2
through 4, this triple combination often eradicated established AB1 tumors. To investigate the mechanism for this effect, tu-
mor tissue was dissected out 2 days after the final treatment injection and examined by histology. In each case, the images
shown are representative fields from two similarly-treated mice. Panel A, Paraffin sections of control and treated tumors. Tu-
mor sections were stained with hematoxylin and eosin. AB1 tumors treated with phosphate buffered saline (left panel) were
hypercellular and consisted of sheaf-like arrangements of fusiform cells with plump cytoplasm and no areas of necrosis. In
contrast, AB1 tumors treated with the triple combination (right panel) showed reduced cellularity and replacement of tumor
cells by collections of infiltrating cells with less condensed nuclei, which were found to correlate with F4/80 macrophages
(see Panel D). Panel B, Immunofluorescence analysis of intratumoral CD11c dendritic cells. In the AB1 tumors injected with
phosphate buffered saline as a control, numerous CD11c  dendritic cells were seen, often in clusters as shown in the figure
(left panel). After treatment with the triple combination, fewer DCs were identified and no clusters of DCs were seen (right
panel). Panel C, Immunofluorescence of intratumoral CD8 T cells. For tumors injected with phosphate buffered saline as a
control, relatively few CD8 T cells were seen (left panel). However, after injections with the triple combination, there was a
marked increase in intratumoral CD8 T cells in all tumor sections examined (right panel). Panel D, Immunofluorescence of
intratumoral F4/80 macrophages. AB1 tumors injected with phosphate buffered saline as a control contained many F4/80
intratumoral macrophages (left panel). However, after treatment with the triple combination, a massive infiltration of macro-
phages was apparent in the regressing tumors (right panel).
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Particularly noteworthy was the demonstration by van Mierlo
et al.3 showing that agonistic CD40 antibody could lead to the
rejection of tumors formed by malignant cells that themselves
lack the CD40 receptor, indicating that the primary effect of
this treatment was on the host immune response and not on
the tumor cells themselves. The most likely mechanism for this
effect is the known ability of CD40 stimulation to activate DCs,
which in turn promote effective CD8 T cell responses.26,27
Consequently, it was disappointing that intratumoral injec-
tions of pSP-D-CD40L were ineffective against AB1 tumors
in this mesothelioma model. One explanation is the relative
inefficiency of gene expression from plasmids injected into
tumors, as opposed to intramuscular DNA injections used in
our previous study.28 Further studies are needed to determine
if polymer delivery agents29 or electroporation30 will have
beneficial effects on the antitumor activities of pSP-D-
CD40L and pSP-D-GITRL. In addition, the combination of
effective CD40 stimulation with TLR agonists deserves fur-
ther study.5,10,20,31
TLR stimuli were effective and have already been
shown to have antitumor effects, as shown by a recent study
by Currie et al.32 Combinations of two TLR agonists may be
even more effective, given the synergistic effects on dendritic
cell function by the combination of a MyD88 pathway TLR
agonist like CpG and a TRIF pathway TLR agonist like
poly(I:C).10,33,34
The immunohistological studies shown in Figure 6 are
consistent with current concepts on how an intratumoral
treatment might lead to tumor rejection. The apparent de-
crease in intratumoral DCs following treatment in AB1 me-
sothelioma models (Figure 6B) is consistent with DC activa-
tion, a shift to CCR7 expression, and chemotaxis through
lymphatics to the tumor-draining lymph nodes.1 The appear-
ance of CD8 T cells in the tumors (Figure 6C) is consistent
with the recognized effects of these cytotoxic cells on me-
sothelioma.8,35 The influx of macrophages into regressing
mesothelioma tumors (Figure 6D) is remarkable, although it
is not clear if the macrophages are killing the tumor cells or
simply removing dead tissue. Buhtoiarov et al.36 found that
CD40 stimulation using an agonistic anti-CD40 antibody com-
bined with systemic CpG slowed the growth of B16 melanoma
tumors even in SCID/beige mice lacking T cells and NK cells,
and this effect was abrogated when silica was given to deplete
macrophages. That study suggests that macrophages should be
considered as one possible effector cell for the antitumor effects
of CD40L/TLR agonist combinations.
In conclusion, CpG demonstrated impressive antitumor
effects on established AB1 mesotheliomas, leading to tumor
regression and long term tumor-free survival in the majority
of cases. Intratumoral injections of plasmid DNAs for SP-D-
CD40L, pSP-D-CD40L plus IFN-, or pSP-D-GITRL were
ineffective, possibly reflecting the difficulty of injecting the very
dense tissue formed by AB1 tumors. Further studies are needed
to determine if this difficulty can be circumvented using
polymers or electroporation to improve DNA delivery and
transgene expression. No toxic effects of this treatment were
apparent, however, suggesting further studies of immunother-
apy as a treatment for mesothelioma are warranted.
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